SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.95−0.05 (-1.67%)
Close on Nov 17, 2026Market cap $268.41MP/E –Yield –
SAB Biotherapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
SAB Biotherapeutics's price to book ratio was 1.2× on Nov 11, 2026, against 1.1× a year earlier. Over the last 5 years it ranged from 0.5× to 9.9×, with a median of 1.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.2× | +0.1 |
| 2025 | Dec 31, 2025 | 1.1× | +0.1 |
| 2024 | Dec 31, 2024 | 0.9× | −3.2 |
| 2023 | Dec 29, 2023 | 4.2× | +2.7 |
| 2022 | Dec 30, 2022 | 1.5× | +0.2 |
| 2021 | Dec 31, 2021 | 1.3× | – |
See a number that looks wrong?